Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in DLE/SCLE
NCT04857034Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score at 16 weeks. Started Jul 2021; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on NCT04857034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857034.